Where We Aim to Innovate

Curacle addresses the common pathology of endothelial dysfunction, pioneering new treatmentparadigms across the eye, kidney, brain, cardiovascular, and inflammatory diseases.
Retinal diseases
Kidney diseases
Neurovascular disorders
Ischemic/Thrombotic diseases
Intractable inflammatory diseases
Pipeline Modality Target Indication Development Status Discovery Pre-
Clinical		 Phase 1 Phase 2a Phase 2b Phase 3 Partner
CU01 PO NRF2 / TGF-β Diabetic Nephropathy Completed Phase 2b clinical trial in Korea(2026.1Q)
CU06
(Rivasterat) 		PO Endothelial Dysfunction Blocker Diabetic macular edema / Age-related Macular Degeneration Completed Phase 2a clinical trial in the U.S(2024.1Q)
MT-101 IV(mAb) Tie2 Acute Kidney Injury/ Chronic Kidney Disease Preclinical studies in progress
MT-103
(MMT-205) 		IV(BsAb) Tie2 / VEGF Diabetic macular edema / Age-related Macular Degeneration Global licensing to Memento Medicines (May 2026).
Preclinical studies in progress
MT-201 IV(mAb) Undisclosed Thrombotic Diseases Preclinical studies in progress
MT-202 IV(BsAb) Tie2 / Undisclosed Thrombotic Diseases Preclinical studies in progress
Pipeline Modality Target Indication Development Status Discovery Pre-
Clinical		 Phase 1 Phase 2a Phase 2b Phase 3 Partner
CU71 PO Endothelial Dysfunction Blocker Neurodegenerative Disease Discovery
CU72 PO Undisclosed Idiopathic Pulmonary Fibrosis Discovery
CU73 PO Undisclosed Thrombotic Diseases Discovery
CU03 PO Multi Target Age-related Macular Degeneration Completed Phase 2a clinical trial in Korea(2022.1Q)
CU104 PO Indication expansion of CU06 Ulcerative Colitis Completed Phase 1 clinical trial in the U.S
CU106 PO Indication expansion of CU06 Immuno-Oncology Combination Completed Phase 1 clinical trial in the U.S
MT-102 IV(mAb) Tie2 Cancer Discovery
MT-105 IV(TsAb) Undisclosed Inflammatory Bowel Disease Discovery
MT-40X IV Undisclosed Cancer Discovery
CP01-R01 PO Endothelial Dysfunction Blocker Kidney Failure in Companion Animals Phase 3 clinical trial in dogs ongoing (Korea)